Table 1.
Characteristics of the 18 included studies.
| Study | Trial | No.of randomized participants (Age,y) | Type | Severity | Interventions | End point | Analyzed outcomes |
|---|---|---|---|---|---|---|---|
| Bissonnette 201815 | NCT02400749 | 100 (≧ 18) | Plaque psoriasis | moderate to severe | Apremilast 30mg bid |
16 week | PPPGA, PPPASI-75, DLQI, PPPGA of 0 or 1, AEs |
| Cutolo 201616 | NCT01212757 | 484 (≧ 18) | Psoriatic Arthritis | - | Apremilast 20mg bid; 30mg bid |
16 week | PASI-75, pain (VAS), AEs |
| Edwards 201617 | NCT01212770 | 505 (≧ 18) | Psoriatic Arthritis | - | Apremilast 20mg bid; 30mg bid |
16 week 24 week |
PASI-75, pain (VAS), AEs |
| Gold 201818 | NCT02425826 | 221 (≧ 18) | Plaque psoriasis | moderate | Apremilast 30mg bid |
16 week | PASI-75, sPGA of 0 or 1, DLQI, pruritus (VAS), ScPGAof 0 or 1, AEs |
| Gold 202119 | NCT03721172 | 595 (≧ 18) | Plaque psoriasis | mild to moderate | Apremilast 30mg bid |
16 week | sPGA of 0 or 1, DLQI, ScPGA of 0 or 1, AEs |
| Kavanaugh 201420 | NCT01172938 | 504 (≧ 18) | Psoriatic Arthritis | - | Apremilast 20mg bid; 30mg bid |
16 week 24 week |
PASI-75, pain (VAS), AEs |
| Nash 201821 | NCT01925768 | 219 (≧ 18) | Psoriatic Arthritis | - | Apremilast 30mg bid |
16 week 24 week |
AEs |
| Ohtsuki 201722 | NCT01988103 | 254 (≧ 20) | Plaque psoriasis | moderate to severe | Apremilast 20mg bid; 30mg bid |
16 week | PASI-75, sPGA of 0 or 1, DLQI, pruritus (VAS), AEs |
| Papp 201223 | NCT00773734 | 352 (≧ 18) | Plaque psoriasis | moderate to severe | Apremilast 10mg bid; 20mg bid; 30mg bid |
16 week | PASI-75, sPGA of 0 or 1, DLQI, AEs |
| Strand 2013-124 | NCT00773734 | 352 (≧ 18) | Plaque psoriasis | moderate to severe | Apremilast 10mg bid; 20mg bid; 30mg bid |
16 week | Pruritus (VAS) |
| Papp 201325 | NCT00606450 | 260 (≧ 18) | Plaque psoriasis | moderate to severe | Apremilast 20mg Qd; 20mg bid |
12 week | PASI-75, AEs |
| Papp 201526 | NCT01194219 | 844 (≧ 18) | Plaque psoriasis | moderate to severe | Apremilast 30mg bid |
16 week | PASI-75, sPGA of 0 or 1,DLQI, pruritus (VAS), ScPGA of 0 or 1, NAPSI, AEs |
| Paul 201527 | NCT01232283 | 413 (≧ 18) | Plaque psoriasis | moderate to severe | Apremilast 30mg bid |
16 week | PASI-75, sPGA of 0 or 1, DLQI, pruritus (VAS), ScPGA of 0 or 1, NAPSI, PPPGA of 0 or 1, AEs |
| Reich 201728 | NCT01690299 | 250 (≧ 18) | Plaque psoriasis | moderate to severe | Apremilast 30mg bid |
16 week | PASI-75, sPGA of 0 or 1, DLQI, pain (VAS), pruritus (VAS), ScPGA of 0 or 1, NAPSI, AEs |
| Schett 201229 | NCT00456092 | 204 (≧ 18) | Psoriatic Arthritis | - | Apremilast 20mg bid; 40mg qd |
12 week | DLQI, AEs |
| Strand 2013-230 | NCT00456092 | 204 (≧ 18) | Psoriatic Arthritis | - | Apremilast 20mg bid; 40mg qd |
12 week | pain (VAS) |
| Van 202031 | NCT03123471 | 303 (≧ 18) | Plaque psoriasis | mild to moderate | Apremilast 30mg bid |
16 week | DLQI, ScPGA of 0 or 1, AEs |
| Wells 201832 | NCT01307423 | 528 (≧ 18) | Psoriatic Arthritis | - | Apremilast 20mg bid; 30mg bid |
16 week | PASI-75, pain (VAS), AEs |
PASI, Psoriasis Area Severity Index; sPGA, Static Physician Global Assessment; ScPGA, Scalp Physician’s Global Assessment; PPPGA, Palmoplantar Psoriasis Physician Global Assessment; NPASI, Nail Psoriasis Severity Index; DLQI, Dermatology Life Quality Index; VAS, visual analogue scale; AE, adverse event.